iBio annual operating margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2024
2025
iBio's operating margin was −4,650.50% for fiscal 2025.
View full iBio company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −4,650.50% | +2742.39 pp |
| 2024 | 2024-06-30 | −7,392.89% | −5816.62 pp |
| 2022 | 2022-06-30 | −1,576.27% | −264.13 pp |
| 2021 | 2021-06-30 | −1,312.15% | +41358.12 pp |
| 2019 | 2019-06-30 | −42,670.27% | −10336.18 pp |
| 2018 | 2018-06-30 | −32,334.09% | −28711.25 pp |
| 2017 | 2017-06-30 | −3,622.84% | −2579.28 pp |
| 2016 | 2016-06-30 | −1,043.57% | −683.44 pp |
| 2015 | 2015-06-30 | −360.13% | +1513.04 pp |
| 2014 | 2014-06-30 | −1,873.17% | −1211.11 pp |
| 2013 | 2013-06-30 | −662.07% | +68.32 pp |
| 2012 | 2012-06-30 | −730.38% | +1125.87 pp |
| 2011 | 2011-06-30 | −1,856.25% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2025-09-30 | −5,951.00% | +4255.00 pp |
| Q4 2025 | 2025-06-30 | −2,599.00% | −2221.89 pp |
| Q2 2025 | 2024-12-31 | −2,209.50% | +4010.74 pp |
| Q4 2024 | 2024-06-30 | −1,948.00% | −25.60 pp |
| Q1 2024 | 2023-09-30 | −10,206.00% | −9264.43 pp |
| Q3 2022 | 2022-03-31 | −377.11% | +693.10 pp |
| Q1 2022 | 2021-09-30 | −6,220.24% | −4531.46 pp |
| Q4 2021 | 2021-06-30 | −1,922.40% | +1647.04 pp |
| Q3 2021 | 2021-03-31 | −941.57% | +9909.78 pp |
| Q2 2021 | 2020-12-31 | −1,070.21% | +7707.57 pp |
| Q1 2021 | 2020-09-30 | −1,688.78% | +2789.42 pp |
| Q1 2020 | 2019-09-30 | −3,569.44% | −1329.58 pp |
| Q2 2019 | 2018-12-31 | −10,851.35% | −8096.43 pp |
| Q1 2019 | 2018-09-30 | −8,777.78% | −6152.61 pp |
| Q3 2018 | 2018-03-31 | −4,478.21% | +6159.63 pp |
| Q2 2018 | 2017-12-31 | −2,239.87% | +2193.46 pp |
| Q1 2018 | 2017-09-30 | −2,754.92% | −418.62 pp |
| Q4 2017 | 2017-06-30 | −2,625.17% | −1623.72 pp |
| Q3 2017 | 2017-03-31 | −10,637.84% | −9827.28 pp |
| Q2 2017 | 2016-12-31 | −4,433.33% | −2751.24 pp |
| Q1 2017 | 2016-09-30 | −2,336.30% | −1203.17 pp |
| Q4 2016 | 2016-06-30 | −1,001.45% | −401.45 pp |
| Q3 2016 | 2016-03-31 | −810.55% | −326.89 pp |
| Q2 2016 | 2015-12-31 | −1,682.09% | −1228.14 pp |
| Q1 2016 | 2015-09-30 | −1,133.13% | −960.23 pp |
| Q4 2015 | 2015-06-30 | −600.00% | −39.02 pp |
| Q3 2015 | 2015-03-31 | −483.67% | −272.65 pp |
| Q2 2015 | 2014-12-31 | −453.95% | +10.15 pp |
| Q1 2015 | 2014-09-30 | −172.89% | +438.54 pp |
| Q4 2014 | 2014-06-30 | −560.98% | +25.92 pp |
| Q4 2013 | 2013-06-30 | −211.02% | +932.38 pp |
| Q1 2013 | 2012-09-30 | −464.10% | +261.68 pp |
| Q4 2012 | 2012-06-30 | −611.43% | +1029.79 pp |
| Q3 2012 | 2012-03-31 | −586.89% | — |
| Q2 2012 | 2011-12-31 | −1,143.40% | — |
| Q1 2012 | 2011-09-30 | −725.78% | — |
| Q3 2011 | 2011-03-31 | −1,641.22% | — |
Over the last five reported fiscal years, iBio's operating margin increased from −32,334.09% to −4,650.50%, a change of +27683.59 percentage points. The latest reported quarter, Q1 2026, shows −5,951.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review iBio filings at SEC.gov ↗